Aditxt Inc (ADTX)

$0.93 0.00 (-0.45%)
Market Cap 4.65M
Revenue (ttm) 130,000.00
Net Income (ttm) -34.45M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -26,500.00%
Debt to Equity Ratio 0.00
Volume 43,800
Avg Vol 658,354
Day's Range N/A - N/A
Shares Out 4.98M
Stochastic %K 15%
Beta 1.51
Analysts Strong Buy
Price Target $61.00

Company Profile

Aditxt, Inc., a commercial-stage company, discovers and develops products in the areas of immune health, precision health, population health, women's health, and neurologic health. The company develops AditxtScore that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 870 1200
Address:
2569 Wyandotte Street, Suite 101, Mountain View, United States
exile0002
exile0002 Sep. 6 at 9:24 PM
$ADTX i think yes, there is no control in this fraud us stockmarket ....
0 · Reply
StOnX13
StOnX13 Sep. 6 at 7:35 PM
$ADTX Can ADTX reverse split again before march 17th 2026 since they reverse split 250 to 1 last march
0 · Reply
jaetee66
jaetee66 Sep. 5 at 8:14 PM
$ADTX
0 · Reply
apache007
apache007 Sep. 5 at 5:33 PM
$ADTX i start to by... prepared to by 200k shares lets see 1.20 EOD...
1 · Reply
manard85
manard85 Sep. 5 at 4:11 PM
$ADTX
0 · Reply
exile0002
exile0002 Sep. 5 at 2:08 PM
$ADTX you mean after next RS ... ok 👍
1 · Reply
apache007
apache007 Sep. 5 at 2:07 PM
$ADTX M.A.200: 19$ market watch target:600$
0 · Reply
simonsteve
simonsteve Sep. 4 at 10:11 PM
$ADTX my precious 🥹🥹🥹🥲🥲🥲
0 · Reply
exile0002
exile0002 Sep. 4 at 8:43 PM
$ADTX hey sorry ....... this nothing else than f r a u d !!!!!!!!! Forget this SEC guys, they are worthless !!!
0 · Reply
exile0002
exile0002 Sep. 4 at 8:18 PM
$ADTX and Saundra ...
0 · Reply
Latest News on ADTX
Aditxt's Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030

Aug 25, 2025, 9:15 AM EDT - 13 days ago

Aditxt's Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030

Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law

Aug 21, 2025, 8:56 AM EDT - 17 days ago

Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law

FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis

Aug 19, 2025, 9:39 AM EDT - 19 days ago

FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis

Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update

Aug 14, 2025, 8:46 AM EDT - 24 days ago

Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update

Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio™ Initiative

Aug 11, 2025, 8:30 AM EDT - 27 days ago

Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio™ Initiative

Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference

Aug 5, 2025, 8:46 AM EDT - 4 weeks ago

Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference

Aditxt's Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology for Early Detection of Cancers and Other Diseases

Jul 29, 2025, 9:00 AM EDT - 5 weeks ago

Aditxt's Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology for Early Detection of Cancers and Other Diseases

Aditxt's Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test

Jul 24, 2025, 8:15 AM EDT - 6 weeks ago

Aditxt's Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test

Aditxt to Present at Wall Street Reporter's Next Super Stock Livestream Today July 22, 2025, at 1 p.m. ET

Jul 22, 2025, 8:15 AM EDT - 6 weeks ago

Aditxt to Present at Wall Street Reporter's Next Super Stock Livestream Today July 22, 2025, at 1 p.m. ET

Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy

Jul 15, 2025, 9:12 AM EDT - 7 weeks ago

Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy

Aditxt Unveils bitXbio™: A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization

Jul 7, 2025, 8:15 AM EDT - 2 months ago

Aditxt Unveils bitXbio™: A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization

Aditxt to Present at Wall Street Reporter's NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET

Jun 26, 2025, 8:15 AM EDT - 2 months ago

Aditxt to Present at Wall Street Reporter's NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET

Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting

Jun 11, 2025, 8:14 AM EDT - 3 months ago

Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting

Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

Jun 9, 2025, 8:15 AM EDT - 3 months ago

Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6

Jun 5, 2025, 8:15 AM EDT - 3 months ago

Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6

Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics

May 19, 2025, 8:00 AM EDT - 3 months ago

Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics

Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™

May 2, 2025, 9:00 AM EDT - 4 months ago

Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™

Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™

Apr 17, 2025, 8:15 AM EDT - 5 months ago

Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

Apr 16, 2025, 8:15 AM EDT - 5 months ago

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

Apr 14, 2025, 8:15 AM EDT - 5 months ago

Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements

Apr 11, 2025, 8:15 AM EDT - 5 months ago

Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements

Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements

Apr 9, 2025, 8:15 AM EDT - 5 months ago

Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements

Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025

Apr 2, 2025, 8:15 AM EDT - 5 months ago

Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025

Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection

Mar 28, 2025, 8:15 AM EDT - 5 months ago

Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection

Evofem Reports Fourth Consecutive Year of Net Sales Growth

Mar 24, 2025, 8:30 AM EDT - 5 months ago

Evofem Reports Fourth Consecutive Year of Net Sales Growth

Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk

Mar 24, 2025, 8:15 AM EDT - 5 months ago

Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk

Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025

Mar 17, 2025, 8:15 AM EDT - 6 months ago

Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-250 Reverse Stock Split Effective at the Open of Trading on March 17, 2025

Mar 12, 2025, 4:15 PM EDT - 6 months ago

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-250 Reverse Stock Split Effective at the Open of Trading on March 17, 2025

Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.

Mar 6, 2025, 8:15 AM EST - 6 months ago

Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.

Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025

Feb 21, 2025, 8:15 AM EST - 7 months ago

Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025

Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time

Feb 13, 2025, 8:15 AM EST - 7 months ago

Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time

Aditxt's Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform

Jan 13, 2025, 8:15 AM EST - 8 months ago

Aditxt's Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

Dec 12, 2024, 8:15 AM EST - 9 months ago

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

Nov 14, 2024, 4:36 PM EST - 10 months ago

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Nov 8, 2024, 8:30 AM EST - 10 months ago

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Nov 7, 2024, 8:30 AM EST - 10 months ago

Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem

Nov 6, 2024, 8:30 AM EST - 10 months ago

Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem

Evofem Secures Investor Support for Proposed Merger through Voting Agreements

Nov 6, 2024, 8:00 AM EST - 10 months ago

Evofem Secures Investor Support for Proposed Merger through Voting Agreements

Aditxt's Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Oct 31, 2024, 8:30 AM EDT - 11 months ago

Aditxt's Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time

Oct 30, 2024, 5:00 PM EDT - 11 months ago

Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time

Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives

Oct 29, 2024, 8:15 AM EDT - 11 months ago

Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives

Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem

Oct 28, 2024, 8:15 AM EDT - 11 months ago

Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem

Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time

Oct 21, 2024, 8:15 AM EDT - 11 months ago

Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time

Aditxt's Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili's Shareholder Approval

Oct 10, 2024, 8:15 AM EDT - 11 months ago

Aditxt's Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili's Shareholder Approval

Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time

Oct 9, 2024, 10:52 AM EDT - 11 months ago

Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time

Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem

Oct 8, 2024, 8:15 AM EDT - 11 months ago

Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem

Aditxt Delivers Shareholder Update and 2024 Year-End Plan

Oct 3, 2024, 8:15 AM EDT - 1 year ago

Aditxt Delivers Shareholder Update and 2024 Year-End Plan

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024

Sep 27, 2024, 8:15 AM EDT - 1 year ago

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024

Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt

Sep 24, 2024, 8:15 AM EDT - 1 year ago

Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt

Aditxt's Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025

Sep 20, 2024, 8:15 AM EDT - 1 year ago

Aditxt's Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025

exile0002
exile0002 Sep. 6 at 9:24 PM
$ADTX i think yes, there is no control in this fraud us stockmarket ....
0 · Reply
StOnX13
StOnX13 Sep. 6 at 7:35 PM
$ADTX Can ADTX reverse split again before march 17th 2026 since they reverse split 250 to 1 last march
0 · Reply
jaetee66
jaetee66 Sep. 5 at 8:14 PM
$ADTX
0 · Reply
apache007
apache007 Sep. 5 at 5:33 PM
$ADTX i start to by... prepared to by 200k shares lets see 1.20 EOD...
1 · Reply
manard85
manard85 Sep. 5 at 4:11 PM
$ADTX
0 · Reply
exile0002
exile0002 Sep. 5 at 2:08 PM
$ADTX you mean after next RS ... ok 👍
1 · Reply
apache007
apache007 Sep. 5 at 2:07 PM
$ADTX M.A.200: 19$ market watch target:600$
0 · Reply
simonsteve
simonsteve Sep. 4 at 10:11 PM
$ADTX my precious 🥹🥹🥹🥲🥲🥲
0 · Reply
exile0002
exile0002 Sep. 4 at 8:43 PM
$ADTX hey sorry ....... this nothing else than f r a u d !!!!!!!!! Forget this SEC guys, they are worthless !!!
0 · Reply
exile0002
exile0002 Sep. 4 at 8:18 PM
$ADTX and Saundra ...
0 · Reply
souljamike
souljamike Sep. 4 at 8:10 PM
$ADTX i seriously considered voting to fire Amro 😂
1 · Reply
souljamike
souljamike Sep. 4 at 8:09 PM
$ADTX robinhood emailed me an invite to vote ahead of the Sep 16 meeting. Voting ends Sep 15
0 · Reply
USNBullJones
USNBullJones Sep. 4 at 7:47 PM
$ADTX I do not see any press release or sec filings regarding alleged reverse splits or intent to issue shares. Is there a scheduled special meeting of shareholders to vote on some corporate action? If so, when specifically and can you provide a source reference?
1 · Reply
exile0002
exile0002 Sep. 4 at 7:37 PM
$ADTX is this management still in prison ? crooks !!!!!
0 · Reply
ThomasJerryLLC
ThomasJerryLLC Sep. 4 at 6:42 PM
$ADTX Aditxt investors. Amro = Frodo
0 · Reply
exile0002
exile0002 Sep. 4 at 6:21 PM
$ADTX this f..... crooks ..... unbelievable !!!!!!
0 · Reply
souljamike
souljamike Sep. 4 at 5:45 PM
$ADTX oh i can vote too. Im voting no RS, no more dilution 😡
0 · Reply
exile0002
exile0002 Sep. 4 at 5:25 PM
$ADTX biggest trash in market !! Fraud sgainst SH !!👎👎👎
0 · Reply
MrAlientrader
MrAlientrader Sep. 4 at 5:00 PM
$ADTX another scam here
0 · Reply
CheesyRegard
CheesyRegard Sep. 4 at 2:10 PM
$ADTX After the last RS was approved, Amro diluted the stock 5000% in 3 weeks, then told investors his dilution was "not aggressive". ADTX is out of cash and past due on the majority of their accounts payable. Amro will gladly sacrifice your equity over sacrificing the well being of himself and his employees. Why do you think he choose 250:1 ratio when the stock is still at $1?
0 · Reply
exile0002
exile0002 Sep. 4 at 1:07 PM
$ADTX clearly there is no RS neccessary now .... but i am sure, we will see a nice offering prior to the RS ........ 👎👎👎
0 · Reply
flyingcoyote
flyingcoyote Sep. 4 at 11:58 AM
$ADTX 1:250 RS would result in 20,000 total outstanding shares.
0 · Reply